SRSF2 and myelodysplastic syndrome: In 90% of cases, MDS patients have gene mutations affecting genes from different classes: epigenetic regulators (DNA methylation or chromatin compaction such as TET2, ASXL1, DNMT3A), spliceosome genes (SF3B1, SRSF2, ZRSR2), transcription factors (TP53, RUNX1, ETV6), genes involved in signaling pathways (N/KRAS, JAK2, CBL), or in the cohesin complex (STAG2, RAD21) [28].